William Weldon really is a piece of work. In January he told analysts the consumer products plant in Fort Washington, PA, would open in 2013.
Johnson & Johnson's manufacturing overhaul has hit some unexpected roadblocks.
The two research powerhouses will conduct a drug-drug interaction study.
Johnson & Johnson's first-quarter sales may have taken a hit, but its prescription drugs business actually grew.
Manufacturing issues that have led to recalls and product shortages continue to be a drag on the earnings of Johnson & Johnson, but the company saw its first quarter profits rise by double digits.
Alex Gorsky's name has surfaced in the U.S. government's Risperdal marketing lawsuit just weeks before he is supposed to step up into the role of CEO at Johnson & Johnson.
Johnson & Johnson is facing more bad news over its metal-on-metal artificial hip implant products, this time in New Zealand and Australia.
Johnson & Johnson's new Risperdal fine isn't just a whopping big penalty. It's a big stone tossed into the company's legal problems.
Like other juries before it, an Arkansas panel found that the company's Janssen unit soft-pedaled the antipsychotic drug's risks.
The idea is to allow its former contract manufacturer to formulate the cancer drug, and then send it elsewhere for filling and packaging.